Clinical Predictors of Recovery and Complications in the Management of Recent-Onset Renal Failure in Lupus Nephritis: A Chinese Experience

Journal of Rheumatology

Volumn 31, Issue 4, 2004, Pages 701-706

  Liang, Liuqin ^a   Yang, Xiuyan ^a,b   Xu, Hanshi ^a   Zhan, Zhongping ^a   Ye, Yujin ^a   Yu, Xueqing ^a   Chen, Weiying ^a  

^a Dept Rheumatol and Clin Immunol ^*

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cox proportional hazards regression; Lupus nephritis; Prediction analysis; Renal failure

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE;

ADULT; ANEMIA; ARTICLE; CHINESE; COHORT ANALYSIS; CONVALESCENCE; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CHINA; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; FORECASTING; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1842530454     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Austin HA, Balow JE. Natural history and treatment of lupus nephritis. Semin Nephrol 1999;19:2-11.
2. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL. Systemic lupus erythematosus survival patterns: experience with 609 patients. JAMA 1981;245:934-8.
3. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
4. Cheigh JS, Stenzel KH. End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 1993;21:2-8.
5. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982;25:1271-7.
6. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
7. Parisky YR, Yassa NA. Diagnostic use of ultrasound in kidney and bladder. In: Massry SG, Glassock RJ, editors. Textbook of nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 2001:1820-56.
8. Stata Corp. Stata statistical software: Release 6.0. College Station, TX: Stata Corporation; 1999.
9. Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature. Q J Med 1989;72:779-833.
10. Kimberly RP, Lockshin MD, Sherman RL, et al. "End-stage" lupus nephritis: Clinical course to and outcome on dialysis. Medicine 1981;60:277-87.
11. Coplon NS, Diskin CJ, Petersen J, Swenson RS. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 1983;308:186-90.
12. Iseki K, Miyasato F, Oura T, Uehara H, Nishime K, Fukiyama K. An epidemiologic analysis of end-stage lupus nephritis. Am J Kidney Dis 1994;23:547-54.
13. Kimberly RP, Lockshin MD, Sherman RL, Mouradian J, Saal S. Reversible "end-stage" lupus nephritis: Analysis of patients able to discontinue dialysis. Am J Med 1983;74:361-8.
14. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
15. McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31.
16. Austin HA, Boumpas DT. Treatment of lupus nephritis. Semin Nephrol 1996;16:527-35.